ganaxolone Ztalmy
Selected indexed studies
- Ganaxolone: First Approval. (Drugs, 2022) [PMID:35596878]
- Ganaxolone (Ztalmy) for CDKL5 deficiency disorder. (Med Lett Drugs Ther, 2024) [PMID:39137179]
- Ganaxolone. (, 2006) [PMID:35349236]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. (2022) pubmed
- Ganaxolone (Ztalmy) for CDKL5 deficiency disorder. (2024) pubmed
- Ganaxolone: First Approval. (2022) pubmed
- CDKL5 Deficiency Disorder. (1993) pubmed
- Ganaxolone. (2006) pubmed
- Ganaxolone. (2007) pubmed
- Ganaxolone. (2022) pubmed
- Update on Antiseizure Medications 2025. (2025) pubmed
- PCDH19-Related Epilepsy Syndrome: A Comprehensive Clinical Review. (2020) pubmed
- Epilepsy and Cognitive Impairment in Childhood and Adolescence: A Mini-Review. (2023) pubmed